Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.71
+0.93581.54%
Volume:41.01K
Turnover:2.50M
Market Cap:288.16M
PE:20.18
High:61.83
Open:60.98
Low:60.60
Close:60.77
52wk High:64.10
52wk Low:39.36
Shares:4.67M
Float Shares:4.67M
Volume Ratio:3.96
T/O Rate:0.88%
Dividend:1.53
Dividend Rate:2.47%
EPS(TTM):3.06
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Roivant Sciences rises 17.6%

TIPRANKS
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs

MT Newswires Live
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Dow Jones
·
Sep 08

Top Premarket Gainers

MT Newswires Live
·
Sep 08

Roivant Sciences Shares Rise on Positive Mid-Stage Trial Results

Dow Jones
·
Sep 08

Roivant Sciences Jumps After Lung Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 08

Shares of Roivant Sciences up 21.1% Premarket After Experimental Lung Disease Drug Meets Main Goal in Mid-Stage Study

THOMSON REUTERS
·
Sep 08

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live
·
Sep 08

Roivant Says Phase 2 PHocus Trial Shows Mosliciguat Cuts Pulmonary Vascular Resistance 56.3% in PH-ILD

Reuters
·
Sep 08

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live
·
Sep 08

Roivant Sciences Ltd - Phocus Met Its Primary Endpoint

THOMSON REUTERS
·
Sep 08

Roivant Announces Positive Results from Phocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (Ph-Ild) and Unveils Ongoing Phase 3 Phrontier Study

THOMSON REUTERS
·
Sep 08

Roivant Sciences - Mosliciguat Shows Lower Cough Incidence than Placebo in Phocus Study

THOMSON REUTERS
·
Sep 08

Roivant Sciences Ltd - Mosliciguat Observed to be Well Tolerated with a Favorable Safety Profile

THOMSON REUTERS
·
Sep 08

Roivant Sciences Ltd - Study Also Met Its Secondary Endpoints at Week 16

THOMSON REUTERS
·
Sep 08

Guardant Health initiated with a Buy at Rothschild & Co Redburn

TIPRANKS
·
Sep 08

China Securities Reports Medical Device Sector Sustains Earnings Improvement While Medical Services Revenue Grows Steadily

Stock News
·
Sep 08